Loading
Diagnosis information
Core diagnostic criteria, specifiers, differential considerations, and documentation support in one open, scan-friendly view.
All criteria are shown. No expand controls or hidden sections.
Core criterion A
≥3 of the following within days of stopping/reducing an antidepressant (after ≥1 month use): FINISH symptoms — flu-like; insomnia; nausea; imbalance; sensory disturbances; hyperarousal/anxiety
Core criterion B
Clinically significant distress or impairment
Core criterion C
Not due to another medical condition or better explained by another mental disorder
Consistent with [Antidepressant Discontinuation Syndrome] [specifier(s)]. Following reduction in dose or cessation of an antidepressant taken regularly for at least 4 weeks, a cluster of symptoms has emerged within hours to days, including flu-like symptoms (fatigue, myalgia, diaphoresis, nausea); insomnia or vivid dreams; sensory disturbances (electric shock sensations - “brain zaps”, paraesthesia); dizziness or unsteadiness; irritability, anxiety, agitation, or low mood. The presentation is characterised by a clear temporal association with dose change, improvement upon reinstatement or slower taper, and absence of features more consistent with relapse. Risk is highest with shorter-acting agents (paroxetine, venlafaxine) and abrupt cessation. Distinguishing from relapse is critical as management differs fundamentally: discontinuation syndrome warrants a supervised taper; relapse warrants continuation or intensification of treatment.
Adapt this supplied template to the assessment. It is not a substitute for diagnostic reasoning or local documentation requirements.